People · Operator
Named in public records as an officer, director or promoter · active 2009–2017 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Monopar Therapeutics | — | Biotechnology | Series A | $19.6M | $361.5M | 2017 |
| Raptor Pharmaceutical Corp | — | Pharmaceuticals | Series B | $15.1M | $512.1M | 2010 |
| Raptor Pharmaceuticals Corp. | — | Pharmaceuticals | Seed | $2.4M | $90.8M | 2009 |
Raymond W. Anderson at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Raymond W. Anderson on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Christopher M. Starr | 3 | 3 |
| Todd C. Zankel | 2 | 2 |
| Kim R. Tsuchimoto | 2 | 2 |
| Michael J. Brown | 1 | 6 |
| Richard L. Franklin | 1 | 1 |
| Erich W. Sager | 1 | 1 |
| Patrice P. Rioux | 1 | 1 |
| Llew L. Keltner | 1 | 1 |
| Erich Sager | 1 | 1 |
| Chandler D. Robinson | 1 | 1 |
| Andrew P. Mazar | 1 | 1 |
| Thomas E. Daley | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.